Mereo BioPharma Group (MREO) to Release Quarterly Earnings on Wednesday

Mereo BioPharma Group (NASDAQ:MREO - Get Free Report) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Wednesday, May 21st. Analysts expect the company to announce earnings of ($0.01) per share for the quarter.

Mereo BioPharma Group (NASDAQ:MREO - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.01). On average, analysts expect Mereo BioPharma Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Mereo BioPharma Group Stock Performance

NASDAQ MREO opened at $2.32 on Wednesday. Mereo BioPharma Group has a twelve month low of $1.58 and a twelve month high of $5.02. The stock has a market capitalization of $368.88 million, a PE ratio of -38.67 and a beta of 0.53. The stock has a 50-day simple moving average of $2.33 and a 200 day simple moving average of $3.01.

Analysts Set New Price Targets

MREO has been the subject of several research analyst reports. Needham & Company LLC reissued a "buy" rating and set a $7.00 price objective on shares of Mereo BioPharma Group in a research report on Tuesday. JPMorgan Chase & Co. assumed coverage on Mereo BioPharma Group in a research report on Thursday, March 27th. They set an "overweight" rating and a $7.00 price objective for the company. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $7.00 price target on shares of Mereo BioPharma Group in a report on Tuesday, March 18th. Six equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $7.71.

About Mereo BioPharma Group

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.